🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

yilong Wang clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with yilong Wang as lead sponsor. Synced 27 Sep 2026
6Current trials
3Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

yilong Wang is the lead sponsor of 6 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are ALT001 and Vancomycin/tigecycline/polymyxin B. The most-studied condition is Blood-Brain Barrier.

ClinicalTrials.gov trials by status

  • Recruiting350%
  • Not yet open350%

Trials by phase

  • Not applicable467%
  • Phase EARLY_PHASE1233%
01

Clinical trials sponsored by yilong Wang

6 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Expansion Study of ALT001 in Patients With Multiple System Atrophy
NCT07476352 · ClinicalTrials.gov ↗ · Multiple System Atrophy
Drug: ALT001
Phase EARLY_PHASE1 Recruiting 2026-06 China
The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar Type
NCT07514923 · ClinicalTrials.gov ↗ · Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Drug: ALT001
Phase EARLY_PHASE1 Recruiting 2026-06 China
The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction
NCT06374667 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic, Blood-Brain Barrier
Not applicable Recruiting 2024-04 China
The Feasibility and Safety of RK-4 Injection Bypassing Blood-brain Barrier in the Treatment of Acute Large Hemispheric Infarction Using Intracalvariosseous Injection Device
NCT07514949 · ClinicalTrials.gov ↗ · Stroke, Acute Ischemic Stroke, Blood-Brain Barrier
Not applicable Not yet open 2026-04 China
Exploring the Combination of Intracalvariosseous and Intravenous Antibiotics for Moderate to Severe Bacterial Meningitis
NCT07826351 · ClinicalTrials.gov ↗ · Blood-Brain Barrier, Bacterial Meningitis
Not applicable Not yet open 2026-09 China
Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis
NCT07495150 · ClinicalTrials.gov ↗ · Blood-Brain Barrier, Bacterial Meningitis
Not applicable Not yet open 2026-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in yilong Wang trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in yilong Wang trials

7 conditions
Blood-Brain Barrier4Bacterial Meningitis2Multiple System Atrophy1Stroke1Acute Ischemic Stroke1Multiple System Atrophy - Cerebellar Subtype (MSA-C)1Stroke, Acute Ischemic1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China63

A trial with sites in more than one country appears in each of those registers.

05

Questions about yilong Wang trials

How many clinical trials does yilong Wang sponsor?

yilong Wang is the lead sponsor of 6 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are yilong Wang trials recruiting?

Yes. 3 of its 6 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is yilong Wang testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are ALT001 (2) and Vancomycin/tigecycline/polymyxin B (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.